Posted by Michael Wonder on 06 Feb 2023
Endogena Therapeutics receives US FDA fast track designation for EA-2353 for the treatment of retinitis pigmentosa
6 February 2023 - Endogena Therapeutics announced today that the US FDA has designated the investigation of EA-2353 for the treatment of retinitis pigmentosa as a fast track development program.
EA-2353 takes a novel, small molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can potentially preserve or restore visual function.
